Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
MIGDAL HA'EMEQ, Israel, May 03, 2017 -- Enzymotec Ltd. (Nasdaq:ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid-based nutritional ingredients and medical foods, announced today that the Company will release financial results for the first quarter ended March 31, 2017 on Wednesday, May 17, 2017, before the market opens. Following the release, Erez Israeli, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
The conference call is scheduled to begin at 8:30 am ET on Wednesday, May 17, 2017. Participants should dial +1 877-359-9508 (United States) or +1 224-357-2393 (International) with confirmation code #17202050 to access the live call. The call will also be broadcast live over the Internet, hosted in the Investors section of Enzymotec's website at http://edge.media-server.com/m/p/qhzwbm72, and will be archived online within one hour of its completion.
About Enzymotec Ltd.
Enzymotec is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit http://www.enzymotec.com.
Contact: The Ruth Group Tram Bui / Alexander Lobo (646) 536-7035 / 7037 [email protected] [email protected]
